Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation

v3.24.1.u1
Basis of Presentation
6 Months Ended
Mar. 31, 2024
Basis of Presentation [Abstract]  
Basis of Presentation Note 1 – Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements for Veru Inc. (“we,” “our,” “us,” “Veru” or the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting of interim financial information. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. Accordingly, these statements do not include all the disclosures normally required by U.S. GAAP for annual financial statements and should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this report and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2023. The accompanying condensed consolidated balance sheet as of September 30, 2023 has been derived from our audited financial statements. The unaudited condensed consolidated statements of operations and cash flows for the three and six months ended March 31, 2024 are not necessarily indicative of the results to be expected for any future period or for the fiscal year ending September 30, 2024.

The preparation of our unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normally recurring adjustments) necessary to present fairly the financial position and results of operations as of the dates and for the periods presented.

Principles of consolidation and nature of operations: Veru Inc. is referred to in these notes collectively with its subsidiaries as “we,” “our,” “us,” “Veru” or the “Company.” The consolidated financial statements include the accounts of Veru and its wholly owned subsidiaries, Veru International Holdco Inc., Aspen Park Pharmaceuticals, Inc. (APP) and The Female Health Company Limited; The Female Health Company Limited’s wholly owned subsidiary, The Female Health Company (UK) plc (The Female Health Company Limited and The Female Health Company (UK) plc, collectively, the “U.K. subsidiary”); The Female Health Company (UK) plc’s wholly owned subsidiary, The Female Health Company (M) SDN.BHD (the “Malaysia subsidiary”); and Veru International Holdco Inc.’s wholly owned subsidiaries, Veru Biopharma UK Limited, Veru Biopharma Europe Limited, and Veru Biopharma Netherlands B.V. All significant intercompany transactions and accounts have been eliminated in consolidation. The Company is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases (obesity), oncology, and acute respiratory distress syndrome (ARDS). Our drug development program includes enobosarm, a selective androgen receptor modulator, for preferential loss of fat while preventing the loss of muscle and bone, in combination with weight loss drugs, and for the management of advanced breast cancer and sabizabulin, a microtubule disruptor, for the treatment of hospitalized patients with viral induced ARDS. The Company also has the FC2 Female Condom/FC2 Internal Condom® (FC2), an FDA-approved commercial product for the dual protection against unplanned pregnancy and sexually transmitted infections. The Company had ENTADFI® (finasteride and tadalafil) capsules for oral use (ENTADFI), a new treatment for benign prostatic hyperplasia that was approved by the FDA in December 2021. We sold substantially all of the assets related to ENTADFI on April 19, 2023. See Note 15 for additional information. Most of the Company’s net revenues during the three and six months ended March 31, 2024 and 2023 were derived from sales of FC2.

Restatement: In connection with the preparation of its unaudited condensed consolidated financial statements for the three months ended December 31, 2023, the Company identified errors related to the accounting for research and development expenses associated with the Company’s projects with third-party service providers. The Company inaccurately estimated the work completed by the third-party service providers. Refer to Amendment No. 1 to the Company’s Annual Report on Form 10-K/A for the fiscal year ended September 30, 2023, filed with the SEC on April 1, 2024 for more information regarding the restatement of the consolidated financial statements for the fiscal years ended September 30, 2023 and 2022. Due to the inaccurate estimation of the work completed by third-party service providers, the Company understated its operating expenses for research and development for the three and six months ended March 31, 2023. As a result, this report reflects a restatement of the Company’s interim financial statements as of March 31, 2023 and for the three and six months ended March 31, 2023.

A summary of the impact of the error on the unaudited condensed consolidated balance sheet as of March 31, 2023 is as follows:

As of March 31, 2023

As Reported

Adjustment

As Restated

Assets

Prepaid research and development costs

$

5,787,224

$

83,781

$

5,871,005

Total current assets

$

43,288,277

$

83,781

$

43,372,058

Total assets

$

70,253,570

$

83,781

$

70,337,351

Liabilities and Stockholders' Equity

Accrued research and development costs

$

13,786,241

$

(5,012,054)

$

8,774,187

Total current liabilities

$

39,259,798

$

(5,012,054)

$

34,247,744

Total liabilities

$

53,537,668

$

(5,012,054)

$

48,525,614

Accumulated deficit

$

(241,209,283)

$

5,095,835

$

(236,113,448)

Total stockholders' equity

$

16,715,902

$

5,095,835

$

21,811,737

Total liabilities and stockholders' equity

$

70,253,570

$

83,781

$

70,337,351

A summary of the impact of the error on the unaudited condensed consolidated statements of operations for the three and six months ended March 31, 2023 is as follows:

Three Months Ended March 31, 2023

As Reported

Adjustment

As Restated

Research and development

$

22,864,633

$

(5,003,932)

$

17,860,701

Total operating expenses

$

43,510,841

$

(5,003,932)

$

38,506,909

Operating loss

$

(39,418,766)

$

5,003,932

$

(34,414,834)

Loss before income taxes

$

(38,859,465)

$

5,003,932

$

(33,855,533)

Net loss

$

(38,792,906)

$

5,003,932

$

(33,788,974)

Net loss per basic and diluted common shares outstanding

$

(0.48)

$

0.06

$

(0.42)

Six Months Ended March 31, 2023

As Reported

Adjustment

As Restated

Research and development

$

41,608,982

$

(3,137,154)

$

38,471,828

Total operating expenses

$

79,801,055

$

(3,137,154)

$

76,663,901

Operating loss

$

(75,006,925)

$

3,137,154

$

(71,869,771)

Loss before income taxes

$

(75,769,922)

$

3,137,154

$

(72,632,768)

Net loss

$

(75,635,085)

$

3,137,154

$

(72,497,931)

Net loss per basic and diluted common shares outstanding

$

(0.94)

$

0.04

$

(0.90)

With respect to the unaudited condensed consolidated statement of cash flows, all adjustments are to line items within operating cash flows and there was no impact to the subtotal of operating, investing, or financing cash flows for each period.

A summary of the impact of the error on the unaudited condensed consolidated statement of cash flows for the six months ended March 31, 2023 is as follows:

Six Months Ended March 31, 2023

As Reported

Adjustment

As Restated

OPERATING ACTIVITIES

Net loss

$

(75,635,085)

$

3,137,154

$

(72,497,931)

(Increase) decrease in prepaid expenses and other assets

$

4,480,405

$

(851,348)

$

3,629,057

Increase in accrued expenses and other current liabilities

$

1,374,233

$

(2,285,806)

$

(911,573)

Investments in equity securities: Investments in equity securities consist of 3,000 shares of Series A Convertible Preferred Stock (the “BWV Preferred Stock”) of Onconetix, Inc., formerly known as Blue Water Vaccines Inc. (“BWV”). The Company has elected to measure the BWV Preferred Stock using the fair value option, as provided for by FASB Accounting Standards Codification (ASC) 825, Financial Instruments, which allows entities to make an irrevocable election of fair value as the initial and subsequent measurement attribute for certain eligible financial assets and liabilities. Under the fair value option, related gains and losses on the financial instrument will be reflected in non-operating income (expenses) in the Company’s statements of operations. The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument and is irrevocable once elected. Pursuant to this guidance, the carrying value will be adjusted to estimated fair value at the end of each quarter.

Other comprehensive loss: Accounting principles generally require that recognized revenue, expenses, gains and losses be included in net loss. Although certain changes in assets and liabilities, such as foreign currency translation adjustments, are reported as a separate component of the equity section of the accompanying unaudited condensed consolidated balance sheets, these items, along with net loss, are components of other comprehensive loss. For the three and six months ended March 31, 2024 and 2023, comprehensive loss is equivalent to the reported net loss.

Recent accounting pronouncements not yet adopted: In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for the Company’s annual periods for the fiscal year ended September 30, 2025, and subsequent interim periods, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU on its disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for the Company’s annual periods beginning fiscal year ended September 30, 2026, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact of adopting this ASU on its disclosures.

We have reviewed all other recently issued accounting pronouncements and have determined that such standards that are not yet effective will not have a material impact on our financial statements or do not otherwise apply to our operations.